ExThera, a company based outside of Oakland, California, won European regulatory approval for its Seraph 100 Microbind Affinity Blood Filter.
The device removes a variety of pathogens in patients with bloodstream infections thanks to its “sorbent-type” filter. It can remove not only molecular compounds, such as cytokines and endotoxin, but also infectious pathogens such as bacteria, viruses, and fungi directly from whole blood.
The device can help to reduce the load of drug resistant pathogens, as shown in pre-clinical and clinical trials, and so may end up being a common first line of defense against such infectious strains.
“Today marks a definitive turning point in advancing the care of bloodstream infections, the result of years of dedicated research, development and investment,” said Bob Ward, NAE, President and CEO of ExThera, in a press release. “Seraph 100 provides an innovative therapy for rapid and effective treatment of infections that might otherwise pose a devastating risk to patients. We look forward to Seraph 100’s continued success in Europe, while demonstrating its potential to help healthcare providers and their patients around the world.”
Product page: Seraph 100 Microbind Affinity Blood Filter
Flashbacks: Hemopurifier FDA Approved to Filter Ebola Out of Blood in Clinical Study; Hemopurifier Filters Ebola, Hep C, Metastatic Melanoma: Interview with James A. Joyce, CEO of Aethlon Medical; Device Cleans Septicimic Blood Using Novel Protein and Common Dialysis Filters;